Abstract |
In human neuroblastoma SH-SY5Y cell preparations, sigma(1) receptor agonists (+)- pentazocine and 1S,2R-(-)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl) cyclohexylamine ( BD737) competed for [3H] haloperidol binding with K(i) values of 67+/-10 and 14+/-10 nM, respectively. (+)- Pentazocine or BD737 up to 10 microM did not affect basal levels of intracellular Ca(2+) concentration ([Ca(2+)](i)) in these cells, but they significantly reduced muscarine-induced [Ca(2+)](i) changes in a dose-related manner. However, the reduction by (+)- pentazocine was not reversed by the sigma(1) receptor antagonist haloperidol. Further studies showed (+)- pentazocine, BD737 and haloperidol could compete for [3H] quinuclidinyl benzilate binding in SH-SY5Y cells with K(i) values of 0.51+/-0.06, 0.32+/-0.07 and 4.4+/-2.3 microM, respectively. Thus, the inhibitory effects on muscarine-induced [Ca(2+)](i) changes by (+)- pentazocine and BD737 in SH-SY5Y cells were likely due to blockade of muscarinic receptors, not due to sigma(1) receptor activation by these ligands.
|
Authors | Weimin Hong, Linda L Werling |
Journal | European journal of pharmacology
(Eur J Pharmacol)
Vol. 436
Issue 1-2
Pg. 35-45
(Feb 01 2002)
ISSN: 0014-2999 [Print] Netherlands |
PMID | 11834244
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Cyclohexylamines
- Pyrrolidines
- Receptors, sigma
- sigma-1 receptor
- Tritium
- BD 737
- Muscarine
- Haloperidol
- Pentazocine
- Calcium
|
Topics |
- Binding, Competitive
(drug effects)
- Calcium
(metabolism)
- Cyclohexylamines
(metabolism, pharmacology)
- Dose-Response Relationship, Drug
- Haloperidol
(metabolism)
- Humans
- Muscarine
(pharmacology)
- Pentazocine
(metabolism, pharmacology)
- Pyrrolidines
(metabolism, pharmacology)
- Radioligand Assay
- Receptors, sigma
(agonists, metabolism)
- Tritium
- Tumor Cells, Cultured
|